Publicaciones (44) Publicaciones en las que ha participado algún/a investigador/a

2018

  1. MSK1 regulates luminal cell differentiation and metastatic dormancy in ER + breast cancer

    Nature Cell Biology, Vol. 20, Núm. 2, pp. 211-221

  2. 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)

    Annals of Oncology, Vol. 29, Núm. 8, pp. 1634-1657

  3. A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation

    EMBO Molecular Medicine, Vol. 10, Núm. 12

  4. A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: The METTEN study

    Oncotarget, Vol. 9, Núm. 86, pp. 35687-35704

  5. A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade

    Annals of Oncology, Vol. 29, Núm. 1, pp. 170-177

  6. A randomized phase II study evaluating different maintenance schedules of nab-paclitaxel in the first-line treatment of metastatic breast cancer: Final results of the IBCSG 42-12/BIG 2-12 SNAP trial

    Annals of Oncology, Vol. 29, Núm. 3, pp. 661-668

  7. Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial

    The Lancet Oncology, Vol. 19, Núm. 6, pp. 812-824

  8. Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology

    Clinical and Translational Oncology, Vol. 20, Núm. 7, pp. 815-826

  9. Breast cancer in 2017: Spurring science, marking progress, and influencing history

    Nature Reviews Clinical Oncology, Vol. 15, Núm. 2, pp. 79-80

  10. Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2

    European Journal of Cancer, Vol. 103, pp. 147-154

  11. Change in topoisomerase 1–positive circulating tumor cells affects overall survival in patients with advanced breast cancer after treatment with etirinotecan pegol

    Clinical Cancer Research, Vol. 24, Núm. 14, pp. 3348-3357

  12. Complete resolution of dysphagia after sequential Polyflex™ stenting in a case of recurrent anastomotic stenosis in an adult with congenital esophageal atresia

    Revista Española de Enfermedades Digestivas, Vol. 110, Núm. 12, pp. 826-829

  13. Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy

    Melanoma Research, Vol. 28, Núm. 3, pp. 195-203

  14. El urólogo del futuro y las nuevas tecnologías

    Archivos Espanoles de Urologia, Vol. 71, Núm. 1, pp. 142-149

  15. Endocrine therapy-induced alopecia in patients with breast cancer

    JAMA Dermatology, Vol. 154, Núm. 6, pp. 670-675

  16. Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer

    Journal of Clinical Oncology, Vol. 36, Núm. 9, pp. 884-890

  17. Estrés oxidativo en la asfixia perinatal y la encefalopatía hipóxico-isquémica

    Anales de Pediatría: Publicación Oficial de la Asociación Española de Pediatría ( AEP ), Vol. 88, Núm. 4, pp. 228-228

  18. Extracellular HMGA1 promotes tumor invasion and metastasis in triple-negative breast cancer

    Clinical Cancer Research, Vol. 24, Núm. 24, pp. 6367-6382

  19. Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases

    Oncotarget, Vol. 9, Núm. 29, pp. 20617-20630

  20. Inflammatory dermatoses, infections, and drug eruptions are the most common skin conditions in hospitalized cancer patients

    Journal of the American Academy of Dermatology, Vol. 78, Núm. 6, pp. 1102-1109